SCHEMBL5458213

SCHEMBL5458213

CSc1ncc2cc(C(=O)CBr)c(=O)[nH]c2n1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM6B O15054 1/20 0.37
▸ KDM4A O75164 1/20 0.37
▸ KDM4D Q6B0I6 1/20 0.37
▸ HIF1AN Q9NWT6 1/20 0.37
▸ KDM2A Q9Y2K7 1/20 0.37
▸ AHR P35869 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ DYRK1A Q13627 4/20 0.35
▸ DYRK1B Q9Y463 4/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ MEN1 O00255 4/20 0.34
▸ KMT2A Q03164 4/20 0.34
▸ SYK P43405 1/20 0.34
▸ THRB P10828 2/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ PDE4B Q07343 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10323760 0.84 KDM6B (0.50) KDM6BKDM4AKDM4DHIF1ANKDM2A
SCHEMBL5458537 0.84 NPC1 (0.45) KDM6BKDM4AKDM4DHIF1ANKDM2A
SCHEMBL10323979 0.82 DYRK1A (0.45) KDM6BKDM4AKDM4DHIF1ANKDM2A
SCHEMBL20589469 0.80 SYK (0.52) MAPTMEN1KMT2ASYK
SCHEMBL29538008 0.76 MEN1 (0.38) AHRMAPTNPC1RAB9AMEN1
SCHEMBL661610 0.76 MEN1 (0.38) AHRMAPTNPC1RAB9AMEN1
SCHEMBL24669258 0.76 KMT2A (0.34) AHRNPC1RAB9AMEN1KMT2A
SCHEMBL24669277 0.76 HTT (0.38) AHRMAPTNPC1RAB9AMEN1
SCHEMBL5262113 0.75 MEN1 (0.39) AHRMAPTNPC1RAB9AMEN1
SCHEMBL6073419 0.74 MEN1 (0.43) AHRMAPTNPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032518-A1 Compounds and methods of use AMGEN INC. (US) 2007-02-08 — — US disclosed
US-20070032518-A1 Compounds and methods of use AMGEN INC. (US) 2007-02-08 — — US disclosed
US-20070032518-A1 Compounds and methods of use AMGEN INC. (US) 2007-02-08 — — US disclosed
EP-1478645-A2 QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS Amgen Inc. (US) 2004-11-24 — — EP disclosed
US-6822097-B1 THIAZOLE-SUBSTITUTED QUINOLINE DERIVATIVES; ANTICARCINOGENIC AGENTS, ANTISTROKE AGENTS; APOPTOSIS AND CELL PROLIFERATION TREATMENT; NERVOUS SYSTEM DISORDERS AMGEN, INC. 2004-11-23 — — US disclosed
WO-2003066630-A2 QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS AMGEN INC. (US) 2003-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032518-A1 Compounds and methods of use BAX, BAD, CASP3 KDM6B 1992/4885KDM4A 3305/4885KDM4D 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback